These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38042584)

  • 1. Recent advances in immunopeptidomic-based tumor neoantigen discovery.
    Meng W; Schreiber RD; Lichti CF
    Adv Immunol; 2023; 160():1-36. PubMed ID: 38042584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement of Tumor Neoantigen Detection by High-Field Asymmetric Waveform Ion Mobility Mass Spectrometry.
    Meng W; Takeuchi Y; Ward JP; Sultan H; Arthur CD; Mardis ER; Artyomov MN; Lichti CF; Schreiber RD
    Cancer Immunol Res; 2024 Aug; 12(8):988-1006. PubMed ID: 38768391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of mass spectrometry-based MHC immunopeptidome profiling in neoantigen identification for tumor immunotherapy.
    Zhang X; Qi Y; Zhang Q; Liu W
    Biomed Pharmacother; 2019 Dec; 120():109542. PubMed ID: 31629254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A proteogenomic approach to target neoantigens in solid tumors.
    Verma A; Halder A; Marathe S; Purwar R; Srivastava S
    Expert Rev Proteomics; 2020; 17(11-12):797-812. PubMed ID: 33491499
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoantigen-reactive T cells exhibit effective anti-tumor activity against colorectal cancer.
    Yu Y; Zhang J; Ni L; Zhu Y; Yu H; Teng Y; Lin L; Xue Z; Xue X; Shen X; Song H; Su X; Sun W; Cai Z
    Hum Vaccin Immunother; 2022 Dec; 18(1):1-11. PubMed ID: 33689574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoantigens in Hematological Malignancies-Ultimate Targets for Immunotherapy?
    Roerden M; Nelde A; Walz JS
    Front Immunol; 2019; 10():3004. PubMed ID: 31921218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. dbPepNeo: a manually curated database for human tumor neoantigen peptides.
    Tan X; Li D; Huang P; Jian X; Wan H; Wang G; Li Y; Ouyang J; Lin Y; Xie L
    Database (Oxford); 2020 Jan; 2020():. PubMed ID: 32090262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteogenomic Platform for Identification of Tumor Specific Antigens.
    Faktor J; Hernychová L; Vojtěšek B; Hupp T
    Klin Onkol; 2018; 31(Suppl 2):102-107. PubMed ID: 31023032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
    Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
    J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigen discovery for the development of cancer immunotherapy.
    Ahn R; Cui Y; White FM
    Semin Immunol; 2023 Mar; 66():101733. PubMed ID: 36841147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mass Spectrometry Based Immunopeptidomics for the Discovery of Cancer Neoantigens.
    Bassani-Sternberg M
    Methods Mol Biol; 2018; 1719():209-221. PubMed ID: 29476514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor neoantigens: from basic research to clinical applications.
    Jiang T; Shi T; Zhang H; Hu J; Song Y; Wei J; Ren S; Zhou C
    J Hematol Oncol; 2019 Sep; 12(1):93. PubMed ID: 31492199
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy.
    Bai P; Li Y; Zhou Q; Xia J; Wei PC; Deng H; Wu M; Chan SK; Kappler JW; Zhou Y; Tran E; Marrack P; Yin L
    Oncoimmunology; 2021 Jan; 10(1):1868130. PubMed ID: 33537173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy.
    Okada M; Shimizu K; Fujii SI
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269735
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ProGeo-neo: a customized proteogenomic workflow for neoantigen prediction and selection.
    Li Y; Wang G; Tan X; Ouyang J; Zhang M; Song X; Liu Q; Leng Q; Chen L; Xie L
    BMC Med Genomics; 2020 Apr; 13(Suppl 5):52. PubMed ID: 32241270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoantigens in Hematologic Malignancies.
    Biernacki MA; Bleakley M
    Front Immunol; 2020; 11():121. PubMed ID: 32117272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging potential of immunopeptidomics by mass spectrometry in cancer immunotherapy.
    Minegishi Y; Haga Y; Ueda K
    Cancer Sci; 2024 Apr; 115(4):1048-1059. PubMed ID: 38382459
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges targeting cancer neoantigens in 2021: a systematic literature review.
    Chen I; Chen MY; Goedegebuure SP; Gillanders WE
    Expert Rev Vaccines; 2021 Jul; 20(7):827-837. PubMed ID: 34047245
    [No Abstract]   [Full Text] [Related]  

  • 19. IDENTIFICATION OF MHC PEPTIDES USING MASS SPECTROMETRY FOR NEOANTIGEN DISCOVERY AND CANCER VACCINE DEVELOPMENT.
    Chen R; Fulton KM; Twine SM; Li J
    Mass Spectrom Rev; 2021 Mar; 40(2):110-125. PubMed ID: 31875992
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoantigens in precision cancer immunotherapy: from identification to clinical applications.
    Zhang Q; Jia Q; Zhang J; Zhu B
    Chin Med J (Engl); 2022 Jun; 135(11):1285-1298. PubMed ID: 35838545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.